blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2999791

EP2999791 - CAPSID-MODIFIED, RAAV3 VECTOR COMPOSITIONS AND METHODS OF USE IN GENE THERAPY OF HUMAN LIVER CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.10.2019
Database last updated on 05.07.2024
FormerThe patent has been granted
Status updated on  02.11.2018
FormerGrant of patent is intended
Status updated on  24.06.2018
FormerExamination is in progress
Status updated on  14.07.2017
Most recent event   Tooltip23.07.2021Lapse of the patent in a contracting state
New state(s): MT		published on 25.08.2021  [2021/34]
Applicant(s)For all designated states
University of Florida Research Foundation, Inc.
223 Grinter Hall
Gainesville, FL 32611 / US
[2016/13]
Inventor(s)01 / SRIVASTAVA, Arun
3823 SW 92nd Drive
Gainesville, Florida 32608 / US
02 / ZHONG, Li
404 Sargent Road
Boxborough, Massachusetts 01719 / US
03 / ZOLOTUKHIN, Sergei
1122 Sw 96
Gainesville, Florida 32607 / US
04 / ASLANIDI, George V.
2411 NW 69th Terrace
Gainesville, Florida 32626 / US
05 / AGBANDJE-MCKENNA, Mavis
10202 SW 17th Place
Gainesville, Florida 32607 / US
06 / VAN VLIET, Kim M.
8124 SW 57th Place
Gainesville, Florida 32608 / US
07 / LING, Chen
3702 NE 1st Way
Gainesville, Florida 32609 / US
 [2017/52]
Former [2016/13]01 / SRIVASTAVA, Arun
3823 SW 92nd Drive
Gainesville, Florida 32608 / US
02 / ZHONG, Li
404 Sargent Road
Boxborough, Massachusetts 01719 / US
03 / ZOLOTUKHIN, Sergei
1122 Sw 96
Gainesville, Florida 32607 / US
04 / ASLANIDI, George V.
2411 NW 69th Terrace
Gainesville, Florida 32626 / US
05 / AGBANDJE-MCKENNA, Mavis
10202 SW 17th Place
Gainesville, Florida 32607 / US
06 / VAN VLIET, Kim M.
8124 SW 57th Place
Gainesville, Florida 32608 / US
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2016/13]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Application number, filing date14733803.221.05.2014
[2016/13]
WO2014US39015
Priority number, dateUS20131389948121.05.2013         Original published format: US201313899481
[2016/13]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2014193716
Date:04.12.2014
Language:EN
[2014/49]
Type: A2 Application without search report 
No.:EP2999791
Date:30.03.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 04.12.2014 takes the place of the publication of the European patent application.
[2016/13]
Type: B1 Patent specification 
No.:EP2999791
Date:05.12.2018
Language:EN
[2018/49]
Search report(s)International search report - published on:EP22.01.2015
ClassificationIPC:C12N15/864, A61K48/00, A61K49/00
[2016/13]
CPC:
C12N15/86 (EP,KR,US); C07K14/005 (EP,KR,US); A61K35/76 (US);
A61K39/4615 (EP,KR); A61K39/4622 (EP,KR); A61K39/4634 (EP,KR);
A61K39/464457 (EP,KR); A61K48/0008 (US); A61K48/005 (KR,US);
A61K48/0091 (EP,US); A61P1/16 (EP); A61P35/00 (EP);
C12N15/8645 (US); C12N7/00 (US); A61K2039/5158 (US);
C12N2750/14122 (EP,KR,US); C12N2750/14132 (US); C12N2750/14141 (EP,KR);
C12N2750/14142 (US); C12N2750/14143 (EP,US); C12N2750/14145 (EP,US);
C12N2750/14171 (EP,US); C12N2810/6027 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/13]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:KAPSIDMODIFIZIERTE, RAAV3-VEKTORZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG IN DER GENTHERAPIE VON LEBERKREBS BEI MENSCHEN[2018/19]
English:CAPSID-MODIFIED, RAAV3 VECTOR COMPOSITIONS AND METHODS OF USE IN GENE THERAPY OF HUMAN LIVER CANCER[2016/13]
French:COMPOSITIONS DE VECTEUR AAV3 RECOMBINANT À CAPSIDE MODIFIÉE ET UTILISATIONS POUR LA THÉRAPIE GÉNÉTIQUE DU CANCER DU FOIE CHEZ L'HOMME[2018/28]
Former [2016/13]CAPSIDMODIFIZIERTE, RAAV3-VEKTORZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG IN DER GENTHERAPIE VON LEBERKREBS BEI MENSCHEN
Former [2016/13]COMPOSITIONS DE VECTEUR RAAV3 À MODIFICATION CAPSIDIQUE ET PROCÉDÉS D'UTILISATION DANS LA THÉRAPIE GÉNÉTIQUE DU CANCER DU FOIE HUMAIN
Entry into regional phase21.12.2015National basic fee paid 
21.12.2015Designation fee(s) paid 
21.12.2015Examination fee paid 
Examination procedure21.12.2015Examination requested  [2016/13]
01.08.2016Amendment by applicant (claims and/or description)
12.07.2017Despatch of a communication from the examining division (Time limit: M06)
10.01.2018Reply to a communication from the examining division
25.06.2018Communication of intention to grant the patent
25.10.2018Fee for grant paid
25.10.2018Fee for publishing/printing paid
25.10.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18202680.7  / EP3492597
Opposition(s)06.09.2019No opposition filed within time limit [2019/46]
Fees paidRenewal fee
27.05.2016Renewal fee patent year 03
30.05.2017Renewal fee patent year 04
29.05.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.05.2014
AL05.12.2018
CY05.12.2018
CZ05.12.2018
EE05.12.2018
HR05.12.2018
LV05.12.2018
MC05.12.2018
MT05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
LU21.05.2019
[2021/34]
Former [2021/33]HU21.05.2014
AL05.12.2018
CY05.12.2018
CZ05.12.2018
EE05.12.2018
HR05.12.2018
LV05.12.2018
MC05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
LU21.05.2019
Former [2021/26]AL05.12.2018
CY05.12.2018
CZ05.12.2018
EE05.12.2018
HR05.12.2018
LV05.12.2018
MC05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
LU21.05.2019
Former [2020/17]AL05.12.2018
CZ05.12.2018
EE05.12.2018
HR05.12.2018
LV05.12.2018
MC05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
LU21.05.2019
Former [2020/13]AL05.12.2018
CZ05.12.2018
EE05.12.2018
HR05.12.2018
LV05.12.2018
MC05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
BG05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
LU21.05.2019
Former [2020/07]AL05.12.2018
CZ05.12.2018
EE05.12.2018
HR05.12.2018
LV05.12.2018
MC05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
BG05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/50]AL05.12.2018
CZ05.12.2018
EE05.12.2018
HR05.12.2018
LV05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
BG05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/39]AL05.12.2018
CZ05.12.2018
EE05.12.2018
HR05.12.2018
LV05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SK05.12.2018
SM05.12.2018
BG05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/37]AL05.12.2018
CZ05.12.2018
EE05.12.2018
HR05.12.2018
LV05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SM05.12.2018
BG05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/35]AL05.12.2018
CZ05.12.2018
HR05.12.2018
LV05.12.2018
PL05.12.2018
RS05.12.2018
BG05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/33]AL05.12.2018
HR05.12.2018
LV05.12.2018
RS05.12.2018
BG05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/26]AL05.12.2018
HR05.12.2018
LV05.12.2018
RS05.12.2018
BG05.03.2019
GR06.03.2019
Former [2019/25]HR05.12.2018
LV05.12.2018
RS05.12.2018
BG05.03.2019
GR06.03.2019
Former [2019/24]HR05.12.2018
LV05.12.2018
BG05.03.2019
GR06.03.2019
Former [2019/23]HR05.12.2018
LV05.12.2018
BG05.03.2019
Former [2019/22]BG05.03.2019
Cited inInternational search[XI]  - B CHENG ET AL, "Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells", GENE THERAPY, (20110721), vol. 19, no. 4, doi:10.1038/gt.2011.105, ISSN 0969-7128, pages 375 - 384, XP055085860 [X] 1,2,4-8,11,13,15-22,27 * Introduction * * page 378 * * table 1 * * Materials and Methods, paragraph 2;; figures 5, 6 * [I] 3,9,10,12,14,23-26,28-33

DOI:   http://dx.doi.org/10.1038/gt.2011.105
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.